Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06547775 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Apr 30, 2025 to Apr 30, 2027 Completion date: Jun 30, 2025 to Jun 30, 2027v3 Show 1 more changeShow less
    • Completion date: Jun 30, 2025 to Jun 30, 2027
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Aug 15, 2024 to Aug 2, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 15, 2024 to Aug 2, 2024
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN069 in Chinese male participants with Obesity or Overweight.
Trial Details
NCT Number NCT06547775
Lead Sponsor Suzhou Alphamab Co., Ltd.
Conditions Overweight or Obesity
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov